SCHEMBL5529334

SCHEMBL5529334

CC1(C)O[C@H]2[C@H](O1)[C@H](n1cnc3c(Cl)ncnc31)O[C@@H]2c1nnc(C(C)(C)C)o1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PI4KA P42356 1/20 0.44
PI4K2B Q8TCG2 1/20 0.44
PI4K2A Q9BTU6 1/20 0.44
PI4KB Q9UBF8 1/20 0.44
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
TYMP P19971 1/20 0.37
P2RX1 P51575 1/20 0.37
P2RX3 P56373 1/20 0.37
P2RX4 Q99571 1/20 0.37
AMD1 P17707 2/20 0.36
PRMT5 O14744 4/20 0.34
WDR77 Q9BQA1 4/20 0.34
STING1 Q86WV6 1/20 0.33
ADORA3 P0DMS8 1/20 0.32
ADORA2A P29274 1/20 0.32
ADORA2B P29275 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5529325 1.00 PI4KA (0.44) PI4KAPI4K2BPI4K2API4KBPDE4A
SCHEMBL14390216 1.00 PI4KA (0.44) PI4KAPI4K2BPI4K2API4KBPDE4A
SCHEMBL7189813 1.00 PI4KA (0.44) PI4KAPI4K2BPI4K2API4KBPDE4A
SCHEMBL6576927 0.82 TYMP (0.52) PDE4APDE4BPDE4CPDE4DTYMP
SCHEMBL6229115 0.82 ADORA3 (0.54) PI4KAPI4K2BPI4K2API4KBPRMT5
SCHEMBL6253348 0.82 ADORA3 (0.54) PI4KAPI4K2BPI4K2API4KBPRMT5
SCHEMBL5534004 0.82 ADORA3 (0.54) PI4KAPI4K2BPI4K2API4KBPRMT5
SCHEMBL6229111 0.82 ADORA3 (0.54) PI4KAPI4K2BPI4K2API4KBPRMT5
SCHEMBL6796631 0.79 PI4KA (0.46) PI4KAPI4K2BPI4K2API4KBPDE4A
SCHEMBL6572952 0.79 PI4KA (0.46) PI4KAPI4K2BPI4K2API4KBPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7297787-B2 Process for preparing N6 substituted aminopurine ribofuranose nucleosides GLAXO GROUP LIMITED (GB) 2007-11-20 US disclosed
EP-1370569-B1 PROCESS FOR PREPARING N6-SUBSTITUTED AMINOPURINE RIBOFURANOSE NUCLEOSIDES GLAXO GROUP LTD (GB) 2005-08-31 EP disclosed
US-20050176949-A1 Process for preparing N6 substituted aminopurine ribofuranose nucleosides GLAXO GROUP LIMITED (GB) 2005-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176949-A1 Process for preparing N6 substituted aminopurine ribofuranose nucleosides ADORA3, NUDT1, ADORA1 PI4KA 2558/4885PI4K2B 3589/4885PI4K2A 3135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.